Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of aQIV vs aTIV in Older Adults
NCT03314662Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of influenza vaccine (surface antigen, inactivated, adjuvanted) in influenza, sponsored by CSL Seqirus. Started Oct 2017; status: completed.
02
Drugs
influenza vaccine (surface antigen, inactivated, adjuvanted)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03314662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03314662.